Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 8, 2006, Pages 769-775

  Addo Yobo, Steven O ^a   Straessle, Jennifer ^a   Anwar, Adil ^a   Donson, Andrew M ^a   Kleinschmidt Demasters, B K ^a   Foreman, Nicholas K ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Developmental genes; ErbB3; Gefitinib; Pilocytic astrocytoma; Sox10

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR SOX10;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER INCIDENCE; CHOROID PLEXUS TUMOR; DNA MICROARRAY; EPENDYMOMA; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; MOLECULAR MECHANICS; NEURAL CREST; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; RHABDOID TUMOR; WESTERN BLOTTING;

ADOLESCENT; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HIGH MOBILITY GROUP PROTEINS; HUMANS; HYPOTHALAMIC NEOPLASMS; LINKAGE (GENETICS); MALE; NEURAL CREST; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-3; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746882136     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000229989.25171.aa     Document Type: Article

References (29)

1. Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In: Kleihues P, Cavanee WK, eds. Pathology and Genetics: Tumors of the Nervous System. Lyon, France: IARC Press, 2000:45-51
2. Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Central Brain Tumor Registry of the United States (CBTRUS) 2005-2006
3. Morantz RA. Low-grade astrocytomas. In: Kaye AH, Laws ER Jr, eds. Brain Tumours. An Encyclopedic Approach, 2nd ed. London: Churchill Livingstone, 2001:485-88
4. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993;11:850-56
5. Reddy AT, Packer RJ. Chemotherapy for low-grade gliomas. Childs Nerv Syst 1999;15:506-13
6. Schmandt SM, Packer RJ. Treatment of low-grade pediatric gliomas. Curr Opin Oncol 2000;12:194-98
7. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80
8. Lang FF, Miller DC, Pisharody S, et al. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994;9:949-54
9. Platten M, Giordano MJ, Dirven CM, et al. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996;149:621-27
10. Gutmann DH, Donahoe J, Brown T, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-67
11. Foreman NK, Gore L, Wells D, et al. Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. Pediatr Blood Cancer 2005;Oct 3:Epub ahead of print
12. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (GEFITINIB; Iressa) tablets. Clin Cancer Res 2004;10:1212-18
13. Yarden Y, Sliwkowski MX. Untangling the ERBB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
14. Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 2001;11:287-96
15. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-47
16. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-64
17. Henriksson R. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004;108:135-42
18. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15:66-78
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-85
20. Bannykh SI, Stolt CC, Kim J, et al. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol 2006;76:115-27
21. Schlegel J, Stumm G, Brandle K, et al. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994;22:201-207
22. Adlkofer K, Lai C. Role of neuregulins in glial cell development. Glia 2000;29:104-111
23. Soltoff SP, Carraway KL III, Prigent SA, et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-58
24. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67
25. Kuhlbrodt K, Herbarth B, Sock E, et al. Sox10, a novel transcriptional modulator in glial cells. J Neurosci 1998;18:237-50
26. Boon K, Osório E, Greenhut SF, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 2002;99:11287-92
27. Cannella B, Pitt D, Marchionni M, et al. Neuregulin and erbB receptor expression in normal and diseased human white matter. J Neuroimmunol 1999;100:233-42
28. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93
29. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005;93:1334-40